C12N 2740/10051
Methods of production or purification of viral material
C12N2740/10051 (Methods of production or purification of viral material) appears on 58 US grants and 93 published applications in this corpus.
Search patents in C12N- Granted patents
- 58
- Published applications
- 93
- Assignees
- 69
- Inventors
- 186
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 1 | 4 |
| 2003 | 2 | 5 |
| 2004 | 1 | 2 |
| 2005 | 2 | 3 |
| 2006 | 2 | 0 |
| 2007 | 3 | 1 |
| 2008 | 1 | 3 |
| 2009 | 0 | 3 |
| 2010 | 2 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 3 |
| 2013 | 0 | 2 |
| 2014 | 2 | 1 |
| 2015 | 2 | 5 |
| 2016 | 3 | 5 |
| 2017 | 0 | 3 |
| 2018 | 3 | 2 |
| 2019 | 0 | 5 |
| 2020 | 3 | 1 |
| 2021 | 3 | 7 |
| 2022 | 1 | 5 |
| 2023 | 0 | 9 |
| 2024 | 1 | 7 |
| 2025 | 9 | 9 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells2 Sep 2025US 12,404,525 B2President and Fellows of Harvard College
- Virus vector production15 Jul 2025US 12,359,217 B2Fondazione Telethon Ets
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells8 Jul 2025US 12,351,814 B2President and Fellows of Harvard College
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells8 Jul 2025US 12,351,815 B2President and Fellows of Harvard College
- Method for producing high-titer viral vector8 Oct 2026US 2026/0308534 A1Kaneka Corporation
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Use of rtl8-deficient cells to produce biocompatible, peg10-derived virus-like particles (vlp)30 Jul 2026US 2026/0218135 A1The Regents of the University of Colorado, a body corporate
- Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof26 Feb 2026US 2026/0053924 A1
Most cited
By later US patents
- Apparatus and method for electroporation of biological samples114US 7,141,425 B2MaxCyte, Inc. · 2006
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002
- Methods for removal, purification, and concentration of viruses and methods of therapy based thereupon67US 7,160,464 B2The General Hospital Corporation · 2007
- Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon49US 6,861,001 B2The General Hospital Corporation · 2005
- Method for producing virus vector33US 9,102,943 B2Takara Bio Inc. · 2015